FDA Receives New BLA for Dato-DXd in Pretreated EGFR+ Advanced NSCLC
AstraZeneca has filed a new BLA for Dato-DXd in pretreated, EGFR-mutated advanced non–small cell lung cancer.
Related Articles
Bendamustine/Obinutuzumab Induction Generates Favorable Responses and MRD Negativity in Treatment-Naive MCL
Induction therapy with bendamustine plus obinutuzumab resulted in higher CR rates compared with historical rates of CR with BR in treatment-naive MCL.
Data for Nivolumab Plus AVD Could Help Harmonize Treatment of Older and Younger Advanced-Stage Hodgkin Lymphoma
Alex F. Herrera, MD, discusses long-term data from nivolumab plus AVD in advanced-stage Hodgkin lymphoma.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Finding the ‘Right Fit’ for ER+ Breast Cancer After Aromatase Inhibitor AEs
A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.
TAB-Follicular Lymphoma
Advancements in FL treatment, including BTK inhibitors and CAR T-cell therapies, offer new hope for relapsed or refractory cases.
Cilta-Cel Shows ‘Promising Efficacy, Safety’ in Newly Diagnosed MM | Blood Cancers Today
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM who have had suboptimal response to frontline…
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
Jeffrey Graham University of Manitoba Ardalan E. Ahmad University of Manitoba Naveen S. Basappa University of Alberta Jean-Christophe Bernhard CHU de Bordeaux, France Bimal Bhindi…
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis
A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.